tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Phase IIa Results and Favorable Safety Profile Drive Buy Rating for Skye Bioscience’s Nimacimab
PremiumRatingsPromising Phase IIa Results and Favorable Safety Profile Drive Buy Rating for Skye Bioscience’s Nimacimab
21d ago
Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald
21d ago
Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald
21d ago
Skye Bioscience initiated with a Buy at H.C. Wainwright
PremiumThe FlySkye Bioscience initiated with a Buy at H.C. Wainwright
27d ago
Skye Bioscience presents Phase 1b data from nimacimab study
Premium
The Fly
Skye Bioscience presents Phase 1b data from nimacimab study
1M ago
Skye Bioscience’s Nimacimab: Promising Phase IIa Trial Results and Buy Recommendation
Premium
Ratings
Skye Bioscience’s Nimacimab: Promising Phase IIa Trial Results and Buy Recommendation
1M ago
Evercore starts Skye Bioscience at Outperform on nimacimab potential
PremiumThe FlyEvercore starts Skye Bioscience at Outperform on nimacimab potential
2M ago
Skye Bioscience initiated with an Outperform at Evercore ISI
Premium
The Fly
Skye Bioscience initiated with an Outperform at Evercore ISI
2M ago
Skye Bioscience Earnings Call: Positive Outlook Amid Challenges
Premium
Company Announcements
Skye Bioscience Earnings Call: Positive Outlook Amid Challenges
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100